Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06614205

Acronym

DATUM

Enrollment

Registered

2024-09-26

Start date

2024-11-01

Completion date

2025-02-25

Last updated

2026-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningioma of Brain

Keywords

meningioma, theragnostic, dosimetry

Brief summary

The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.

Detailed description

Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.

Interventions

DIAGNOSTIC_TESTtumoral dosimetry by scintigraphy

The tumoral dosimetry has been done on patient after treatment by 177Lu-DOTATATE Theses patients performed a scintigraphy exam at D1, D4 and D7 after the treatment

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* patients treated for menigioma at nancy hospital * patients who performed 3 scintigraphics exams during there treatment

Exclusion criteria

* patients deprived of liberty * patient who refused to collect data retrospectively

Design outcomes

Primary

Measure	Time frame	Description
Diagnostic accuracy for progression free survival	Day 1	Accuracy of tumor dosimetry to predict 6-month progression-free survival.

Secondary

Measure	Time frame	Description
Diagnostic accuracy for overal survival	Day 1	Accuracy of tumoral dosimetry in predicting 6-month overall survival

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 26, 2026